A number of other analysts have also recently commented on ATRA. Mizuho initiated coverage on Atara Biotherapeutics in a research report on Tuesday, January 22nd. They set a buy rating and a $62.00 price objective for the company. ValuEngine cut Atara Biotherapeutics from a strong-buy rating to a buy rating in a research report on Tuesday, February 12th. Cowen reiterated a buy rating on shares of Atara Biotherapeutics in a research report on Tuesday, February 26th. Zacks Investment Research cut Atara Biotherapeutics from a hold rating to a sell rating in a research report on Monday, March 4th. Finally, William Blair reiterated an outperform rating on shares of Atara Biotherapeutics in a research report on Monday, April 1st. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of Hold and an average price target of $43.33.
Atara Biotherapeutics stock opened at $23.99 on Tuesday. The firm has a market cap of $1.15 billion, a P/E ratio of -4.55 and a beta of 2.11. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.96 and a quick ratio of 9.96. Atara Biotherapeutics has a one year low of $23.58 and a one year high of $54.45.
In other Atara Biotherapeutics news, CEO Isaac E. Ciechanover sold 7,800 shares of the company’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $36.14, for a total value of $281,892.00. Following the completion of the sale, the chief executive officer now owns 332,243 shares in the company, valued at $12,007,262.02. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Joe Newell sold 1,500 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $39.96, for a total value of $59,940.00. Following the completion of the sale, the insider now owns 63,646 shares of the company’s stock, valued at approximately $2,543,294.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 129,990 shares of company stock valued at $4,678,666. Company insiders own 10.60% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC lifted its stake in shares of Atara Biotherapeutics by 21.7% in the 1st quarter. FMR LLC now owns 6,417,956 shares of the biotechnology company’s stock valued at $255,114,000 after purchasing an additional 1,143,787 shares during the last quarter. Maverick Capital Ltd. bought a new stake in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $34,613,000. Man Group plc bought a new stake in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $1,128,000. Coastal Investment Advisors Inc. bought a new stake in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $142,000. Finally, Marshall Wace LLP bought a new stake in shares of Atara Biotherapeutics in the 1st quarter valued at approximately $284,000.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Further Reading: What is Blockchain?
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.